<DOC>
	<DOCNO>NCT00980759</DOCNO>
	<brief_summary>This study open-label , multi-institutional , randomized phase II study , design investigate efficacy Extended-field irradiation ( EFI ) reduce recurrence para-aortic lymph node ( PAN ) , also improve disease-free survival locally advanced uterine cervical cancer . Radiotherapy give conformal technique base individually take CT scan cisplatin give concomitantly radiotherapy EFI arm pelvis treatment arm . According past study result , patient hypoxic tumor likely develop distant metastasis include recurrence PAN ( 1-3 ) . This study start examination CA9 ( hypoxia marker ) expression primary cervical tumor randomization expect would differential benefit EFI patient CA9-positive vs CA9-negative tumor . However , study design modify much delay patient CA9-negative tumor . The patient register immediately randomize experimental ( EFI ) control arm ( pelvis treat ) examination CA9 expression later time .</brief_summary>
	<brief_title>Prophylactic Irradiation Para-Aortic Lymph Nodes Locally Advanced Uterine Cervical Cancer</brief_title>
	<detailed_description>Patients primary , untreated , histologically confirm carcinoma uterine cervix include study . Absence metastatic para-aortic lymphadenopathy prerequisite enrollment , confirm image study MRI cover abdomen pelvis , PET/CT scan . The sample size base previous study ( 1-3 ) . Considering disease-free survival experimental arm ( patient treat prophylactic para-aortic LN irradiation ) treat 82 % vs 72 % ( preliminary analysis ) , alpha error 5 % statistical power 90 % ( one-sided ) , total 140 patient treatment arm need . With 10 % follow-up loss take account , total number patient 312 . Above figure calculate basis 80 % statistical power 5 % type I error rate . PAN treat prophylactically experimental arm 45Gy/25F/5week fractionation schedule . Pelvis treat accord individual institute 's practice guideline . Boost treatment enlarge pelvic lymph node residual cervical/ parametrial disease conformal radiation technique allow . Intracavitary radiation give via low-dose-rate high-dose-rate brachytherapy technique . Weekly cisplatin give patient , however , patient 's physical condition allow cisplatin administration , omit . This take account final analysis . The stage presence pelvic lymphadenopathy two stratification factor .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Patients ( adequately clinically stag ) primary , untreated , histologically confirm invasive squamous cell carcinoma , adenocarcinoma , adenosquamous carcinoma uterine cervix , FIGO stage IB1 pelvic lymph node metastasis , IB2 , IIA ( ≥4cm tumor size , pelvic LN metastasis ) , IIB , IIIA , IIIB unilateral pelvic wall extension , IVA 2 . Patients negative , paraaortic lymphadenopathy determine pelvic MRI and/or PET/CT scan . 3 . Patients adequate bone marrow function : ANC great equal 1,500/ul , platelet great equal 100,000/ul beginning . 4 . Patients adequate renal function : creatinine equal less 2.0 mg/dL . 5 . Patients sign approve informed consent authorization 6 . Patients meet preentry requirement specify section 6.0 . 7 . Patients ECOG Performance Status 0 , 1 , 2 Karnofsky Performance Scale 100 , 90 , 80 , 70 , 60 , 50 8 . Age : 18≤age≤80 1 . Stage IIIb bilateral pelvic wall extension stage IVB lesion eligible . 2 . Patients histology squamous , adeno , adenosquamous cell carcinoma 3 . Patients receive prior radiotherapy pelvis total hysterectomy Patients diagnosis malignant tumor non malignant melanoma skin cancer stage I. II papillary , follicular thyroid cancer .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Extended-field Irradiation ( EFI )</keyword>
	<keyword>Cervical cancer</keyword>
	<keyword>Hypoxia</keyword>
	<keyword>Carbonic anhydrase 9 ( CA9 )</keyword>
	<keyword>locally advanced uterine cervical cancer</keyword>
</DOC>